tradingview.comOCT 71 min read$NRIX

Nurix Therapeutics, Inc. (NRIX) Starts Phase 1b/2 CLL Combo Trial Under Roche Pact

Nurix Therapeutics has begun a Phase 1b/2 trial of bexobrutideg and venetoclax for CLL/SLL, part of its Roche collaboration. The study aims to inform future registration strategies and potential antibody combinations.

Original reporting

tradingview.com

Published Oct 7, 2026, 5:00 AM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Oct 7, 2026, 5:07 AM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

Nurix Therapeutics, Inc. (NRIX) Starts Phase 1b/2 CLL Combo Trial Under Roche Pact — source image — Source · tradingview.com

Decision brief

The 30-second read

$NRIXBullishMed

Why it matters

The enrollment marks the first clinical execution milestone, potentially catalyzing short‑term stock movement.

Market read

First‑patient enrollment is a fresh, material event for a US‑listed biotech, likely to attract short‑term trading interest.

What to watch

Roche's involvement could limit Nurix's upside if partnership terms are restrictive.

Relevance 8/10Novelty 8/10Timing: today

Background

Nurix Therapeutics is developing BTK degrader therapies for blood cancers; Roche is a strategic partner.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$NRIXBullishHigh confidence

Context

Nurix Therapeutics enrolled its first patient in a Phase 1b/2 CLL/SLL trial under its Roche collaboration.

Expected impact

potential upside as investors price in early‑stage data expectations

Evidence & confidence

Trial start is a material clinical milestone; biotech stocks often rally on such news.

Market effects

Sector

May boost interest in BTK degrader space and related oncology biotech peers.

Regional

Limited to US biotech sector.

Global

Modest; primarily affects investors tracking early‑stage oncology pipelines.

Counterpoint

What could challenge this read

Trial start does not guarantee efficacy; investors may wait for data before committing.

Key entities

company
Nurix Therapeutics, Inc.
US‑listed biotech developing BTK degrader programs.
company
Roche
Pharmaceutical partner collaborating on the trial.

Read at source ← All news

OCT 7

$NRIXLowAI 8/10

Nurix enrolls first patient in bexobrutideg combination trial

Nurix Therapeutics (NASDAQ:NRIX) enrolled the first patient in a Phase 1b/2 trial for bexobrutideg combined with venetoclax to treat chronic lymphocytic leukemia and small lymphocytic lymphoma. The study, conducted with Roche, will assess safety, tolerability, and clinical activity, with potential expansion to other B-cell malignancies. Data may inform future development strategies. Bexobrutideg is also being evaluated in other trials for CLL.

investing.com2 min

OCT 7

$NRIXMed

Nurix Therapeutics Announces First Patient Enrolled in Phase 1b/2 Combination Study of Bexobrutideg in Chronic Lymphocytic Leukemia

Nurix Therapeutics (NRIX) has enrolled the first patient in a Phase 1b/2 study of bexobrutideg combined with venetoclax for chronic lymphocytic leukemia (CLL). The trial, part of a collaboration with Roche, aims to evaluate safety, tolerability, and clinical activity. Data may inform future development strategies for CLL and other B-cell malignancies.

globenewswire.com3 min

OCT 5

$NRIXLow

Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead Sciences

Nurix Therapeutics (NRIX) and Gilead Sciences extended their oncology research collaboration by two years. Nurix will receive a $10M extension fee and could earn up to $1.3B in milestones. Nurix retains co-development and 50/50 profit-sharing options for up to two programs in the U.S.

globenewswire.com2 min

SEP 15

$NRIXHighAI 9/10

NRIX Stock Surges Nearly 70% Premarket Today – Roche And Nurix’s Blood Cancer Drug Collaboration Can Tap A $41B Market

Nurix Therapeutics (NRIX) shares rose 50% premarket after a $2.3B deal with Roche (RHHBY) to develop blood cancer therapy bexobrutideg. Roche will pay $700M upfront, with potential milestone payments. The drug targets a $41B market, including chronic lymphocytic leukemia.

stocktwits.com2 min

AUG 5

$NRIXMed

Nurix Receives $10M Payment as Sanofi Initiates Phase 1 Trial of STAT6 Degrader SAR448272

Nurix said Sanofi began a Phase 1 first-in-human trial of SAR448272/NX-3911, an oral STAT6 degrader, triggering a $10 million milestone payment. Nurix reported it has received about $139 million from its 2019 Sanofi collaboration and remains eligible for about $453 million in further STAT6-related milestones. Sanofi runs the trial, with U.S. co-development and co-promotion options for Nurix.

clinicaltrialvanguard.com3 min

JUL 9

$NRIXMedAI 8/10

Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Nurix Therapeutics (Nasdaq: NRIX) reported fiscal Q2 2026 results and a corporate update. It entered a global Roche collaboration for bexobrutideg (NX-5948) with up to $2.3B total payments, including a $700M upfront. Nurix said EHA data showed CLL/SLL ORR of 83% (PFS 22.1 months) and cash of $443.5M as of May 31, 2026.

manilatimes.net6 min